M. E. Garza
Contributor since: 2009
Company: BioMedReports.Com
Latest Articles
Imprimis' Platform Set To Bring Library Drug Formulations Quickly To Market
With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
Taking Note Of IntelliPharmaCeutics' Now Imminent FDA Decision
AVEO Management Excited About Statistically Significant Improvement Shown In Phase III TIVO-1 Trial
Neptune's Dividend Catalyst Finally In Play
Medgenics: Former CEO Of Celgene Believes In His Newest Biotech Venture
Can Array BioPharma's Breakout Run Hold Or Continue?
Confirmation Of Anticipated Catalyst Likely To Fuel Neptune's Share Prices
Will Shares Of Aastrom Really Triple From Today's Levels Within A Year?
2 Healthcare Stocks That May Surprise In The Near Term
Darling Dendreon Takes Hits As Speculators Continue To Bet On Immunotherapy Plays
Frost Swoops In To Buy More Cheap Prolor Biotech Shares
Adventrx CEO Attempting To Prime His Firm For A Comeback
Incyte's Potential Blockbuster Pipeline Asset Makes It An Attractive Takeover Target
Pozen Shares On The Rebound Since European Migraine Licensing Deal
Closer Look: OMPI's Acquisition Rumors And Price Targets
Should Biotech Investors Start Paying Attention To Parasitic Pig Worms And Autoimmune Diseases?
Are Tides Changing For Herbalife After Massive Sell-Off?
Is The Novavax 'New Paradigm' Worth A Second Look?
Q&A: Astex CEO Focused On Creating Value For Investors In 2012
Solid Fundamental Bet: Shares Of Marine Omega-3 Phospholipids Leader Ready Climb
Insider Buy At Novavax Spurs Speculation
Krill Oil Based Drug Candidate Could Unseat Glaxo's Blockbuster Lovaza
Why Ampio's Big Rebound Run May Not Be Done
President Of Prolor Biotech Bullish About His Firm's Pipeline And Positioning
Corcept Therapeutics: Is There More To Come?
Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising
Closer Look: BioLineRx Snags Another Hep-C License Agreement
2 Biotechs On Teva's Radar Screen
Neurocrine Biosciences Still Worth Watching
OncoSec Medical's President And CEO Lists His Firm's 2012 Milestones
More Drama From Cell Therapeutics